Copyright
©The Author(s) 2020.
World J Gastroenterol. Nov 21, 2020; 26(43): 6891-6908
Published online Nov 21, 2020. doi: 10.3748/wjg.v26.i43.6891
Published online Nov 21, 2020. doi: 10.3748/wjg.v26.i43.6891
Provider diagnostic challenges | Number of countries | Number of studies |
Difficulty differentiating between Crohn’s and ITB | 10 | 36 |
Low disease index of suspicion/clinical awareness due to perceived rarity of Crohn’s leads to underdiagnosis | 8 | 17 |
Lack of quality diagnostic facilities and investigational modalities | 8 | 14 |
Difficulty differentiating between Crohn’s and other infectious diseases | 7 | 16 |
Difficulty differentiating between Crohn’s and UC | 5 | 7 |
Diagnosis of Crohn’s made on histological exam of resected colon | 2 | 3 |
Lack of reliable TB testing modalities | 2 | 2 |
Provider Management Challenges | ||
Use of biologics is limited due to cost | 1 | 3 |
High risk of TB infection reactivation in patients treated with biologics | 1 | 1 |
Patient Access Barriers | ||
Lack of access to high quality health care services | 4 | 9 |
Lack of education/knowledge about disease | 3 | 3 |
Lack of access to Crohn’s medications | 1 | 1 |
Patient Financial Barriers | ||
Patients unable to afford treatment in general (medications and surgeries) | 6 | 9 |
High cost of diagnostic testing | 3 | 4 |
Lack of insurance coverage | 2 | 4 |
Patients unable to afford biologics | 1 | 3 |
- Citation: Rajbhandari R, Blakemore S, Gupta N, Adler AJ, Noble CA, Mannan S, Nikolli K, Yih A, Joshi S, Bukhman G. Crohn’s disease in low and lower-middle income countries: A scoping review. World J Gastroenterol 2020; 26(43): 6891-6908
- URL: https://www.wjgnet.com/1007-9327/full/v26/i43/6891.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i43.6891